Carcinogenicity testing of IL-10: principles and practicalities

Area of Science:

• Immunology
• Toxicology
• Drug Development

Background:

• Interleukin-10 (IL-10) is a crucial cytokine regulating immune responses.
• Recombinant human IL-10 (rhuIL-10) is being developed for chronic diseases.
• Carcinogenicity testing for rhuIL-10 has been a subject of debate.

Purpose of the Study:

• To critically evaluate the feasibility and necessity of carcinogenicity testing for rhuIL-10.
• To review the physiological functions of IL-10 in humans and rodents.
• To assess potential testing procedures and challenges for a recombinant immunogenic protein.

Main Methods:

• Review of IL-10 physiological functions across species.
• Evaluation of carcinogenicity testing approaches for rhuIL-10.
• Analysis of data from transgenic mice and cell line studies.
• Consideration of species-specific differences in IL-10 activity.

Main Results:

• Significant species differences exist in IL-10's physiological roles.
• Carcinogenicity testing of rhuIL-10 in rodents presents practical and theoretical challenges.
• In vitro and in vivo data provide no indication of carcinogenic risk from rhuIL-10.

Conclusions:

• Prolonged administration of rhuIL-10 is unlikely to pose a carcinogenic risk to humans.
• Carcinogenicity testing for rhuIL-10 is considered infeasible and lacks theoretical justification.
• Objective evaluation of necessity and feasibility is crucial for toxicity studies of recombinant proteins.